Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Pharmacokinetics
Study data from Nanjing Medical University, Department of Clinical Pharmacology provide new insights into pharmacokinetics
November 9th, 2008
Scientists discuss in 'Bioequivalence and pharmacokinetic comparison of a single 200-mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy chinese adult male volunteers: a randomized sequence, open-label, two-period crossover study' new findings in pharmacokinetics. According to recent research from Nanjing, People's Republic of China, "Meclofenoxate hydrochloride is a psychostimulant in the nootropic agent group available in capsule and tablet formulations approved for traumatic cataphora, alcoholic poisoning, anoxia neonatorum, and children's enuresis in China. Although these 2 generic formulations are marketed in China, information regarding their...
Source: Medical Letter on the CDC & FDA (2008-11-09)
|
